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Background/aim: Acute rheumatic fever and rheumatic heart disease are major causes of morbidity and mortality in developing
countries. Genetic studies have determined that the immune response in rheumatic heart disease is genetically controlled and that there
is a close relationship between the gene of concern and the class II human leukocyte antigen (HLA) gene. The aim of this study was to
evaluate the relationship of serum HLA-B alleles and tumor necrosis factor alpha (TNF-α) with rheumatic heart disease.
Materials and methods: A total of 50 consecutive patients with rheumatic heart disease and 50 controls were enrolled in the study. HLA
alleles were analyzed using sequence-specific primer-polymerase chain reaction and nucleotide sequencing.
Results: The HLA-B35 allele was significantly more common in patients with rheumatic heart disease than the control group (P =
0.043). The HLA-B44 allele was significantly more common in control patients than in patients with rheumatic heart disease (P = 0.014).
There was a significant inverse correlation between high-sensitivity C-reactive protein and mitral valve area (P = 0.001). There was no
correlation between TNF-α levels and mitral valve area (P = 0.066).
Conclusion: Our findings confirmed the association between HLA-B alleles and rheumatic heart disease.
Key words: Rheumatic heart disease, human leukocyte antigen B subgroups, tumor necrosis factor alpha

1. Introduction
Acute rheumatic fever (ARF) is a nonsuppurative
multisystem autoimmune disease occurring after upper
respiratory tract infection due to Group A streptococci
with a common involvement of joints and heart, but rare
involvement of the central nervous system, skin, and
subcutaneous tissue (1). Although studies conducted in
industrialized countries have demonstrated a decrease
in the incidence of ARF and rheumatic heart disease (RHD),
it is still a medical and public health problem in developing
countries. Approximately 15 million people are estimated
suffer from rheumatic valvular disease worldwide.
Rheumatic valvular disease is a multifactorial process
that appears to be caused by the interaction of risk factors
such as genetic, inflammatory, autoimmune, infectious,
and oxidative stress; however, the pathophysiology are not
completely understood (2). Genetic studies have determined
that the immune response in this disease is genetically
controlled and that there is a close relationship between the
gene of concern and the class II human leukocyte antigen
(HLA) gene. However, various HLA-DR studies and
studies conducted in ethnic groups have reported that the

relationship between the susceptibility to ARF and the class
II HLA gene can be quite variable and that a susceptibility
gene, rather than a specific allele, located in or near this
location may be responsible for this susceptibility (3–5).
However, there have been controversial results
regarding the susceptibility or protective alleles (6).
Tumor necrosis factor-alpha (TNF-α) is one of the most
important cytokines in the pathogenesis of rheumatic
diseases. The lack of a definitive diagnosis of the disease and
the ongoing existence of morbidity and mortality caused
by cardiac involvement are indicative of the necessity to
improve new diagnostic and treatment modalities. In this
study, we aimed to evaluate whether there is a relationship
between rheumatic heart disease and HLA-B and TNF-α.
2. Materials and methods
2.1. Study design
In this study, we enrolled a total of 50 patients with
diagnosed RHD and 50 healthy control subjects. The
physical examinations and echocardiography assessments
of the control subjects were normal. In the medical history
of patients, we inquired about the major findings of the
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first episode of ARF, time and age of the first episode, and
the existence and number of valvular involvements. The
control subjects and the patients with RHD were selected
from among patients with no other diseases that may
affect the anatomy and function of the heart valves, who
signed informed consent forms and agreed to participate
as volunteers, in accordance with the European Society
of Cardiology Valvular Heart Disease Guidelines (7).
Patients with abnormal leukocyte and erythrocyte counts,
electrolyte imbalance, or renal and hepatic dysfunction
were excluded from the study. The study was approved on
19 June 2012 in accordance with the assessment of our
local ethics committee.
2.2. Echocardiographic assessment
Echocardiographic evaluation was performed by using a
VIVID 7 Dimension Cardiovascular Ultrasound System
(Vingmed-General Electric) with a 3.5-MHz transducer.
Echocardiographic examinations were performed in
the left lateral decubitus position. Parasternal long- and
short-axis views and apical views were used as standard
imaging windows. Ejection fraction was calculated by
using the modified Simpson method. Mitral valve area
(MVA) was calculated by planimetric method in the
parasternal short axis. Mitral jet velocity was calculated
by Doppler echocardiography. Aortic and tricuspid valve
gradients of patients were in the normal range, so these
were not specified numerically. All measurements were
done according to the recommendations of the American
Society of Echocardiography (8).
2.3. Laboratory assessment
HLA genotyping and high-sensitivity C-reactive protein
(hs-CRP) and TNF-α measurements were carried out in
the laboratory of the Department of Pediatric Nephrology.
Genomic DNA from whole blood samples was extracted
by a standard method. In the laboratory environment,
200 mL of blood was collected into an EDTA tube for
HLA typing. The DNA was isolated with an automated
DNA isolation device. The DNA, distilled water, and Taq
polymerase enzyme were mixed in suitable proportions
and the mixture was collected into 0.5-mL PCR tubes and
then placed in a thermal cycler device. DNA amplifications
were performed by selecting the appropriate program
for HLA-B SSO typing study. The results were processed
on a Luminex device after about 4 h of incubation.
DNA isolation was performed automatically with Geno
Geno M-6 device (GenoVision, QIAGEN). Serum
concentrations of TNF-α were determined by enzymelinked immunosorbent assay (ELISA) according to the
manufacturer’s procedure (Cat No: EK0525, Boster
Biological Technology Co., Ltd.). Blood samples were
taken into standardized tubes containing dipotassium
ethylenediaminetetraacetic acid (EDTA) for complete
blood count (CBC). The Coulter Counter LH Series

(Beckman Coulter Inc.) was used for CBC and hs-CRP
analysis.
2.4. Statistical analysis
Statistical analysis was performed with SPSS 16.0 for
Windows (SPSS Inc., Chicago, IL, USA). The normal
distribution of variables and groups was tested with the
Kolmogorov–Smirnov test. The t-test and Mann–Whitney
U test were used for the values given as mean ± standard
deviation and for the comparison of nonparametric
quantitative data, respectively. In addition, the chi-square
test was used for nonnumerical categorical variables.
Pearson’s test was used for the correlation analysis and the
r value (correlation coefficient) was calculated. P < 0.05
was considered statistically significant.
3. Results
Baseline clinical characteristics and laboratory parameters
of the groups are shown in Table 1. The mean age of the
patients was 37.8 ± 7.7 years and the mean age of the
control group was 35.3 ± 6.3 years. All of the patients had
mitral valve involvement, while 44 patients (88%) had
both mitral and aortic valve involvement (Table 2). The
mean MVA was 2.3 ± 0.8 cm2, mean diastolic transmitral
gradient was 4.6 ± 2.3 mmHg, and the average of maximum
diastolic transmitral gradient was 10.8 ± 4.6 mmHg.
There was no difference between the two groups in terms
of hemoglobin, creatinine, or TNF-α levels, whereas the
leukocyte count was significantly higher in patients with
RHD than the control group and the platelet count was
significantly higher in the control group than the patient
group (P < 0.001 and P < 0.001, respectively). The hs-CRP
level was significantly higher in patients with RHD than
the control group [1.58 (0.01–9.88) vs. 0.13 (0–2.05); P <
0.001] (Table 1).
There was no significant difference in the presence of
the HLA-B13, HLA-B27, HLA-B38, HLA-B49, HLA-B51,
and HLA-B52 alleles between the two groups. However,
the HLA-B35 allele was significantly more common
in patients with RHD than the control group, while the
HLA-B44 allele was significantly more common in the
control group than in patients with RHD (Table 3). There
was significant inverse correlation between hs-CRP
and MVA in patients with RHD (r = –0.340, P = 0.001).
However, there was no correlation between TNF-α levels
and MVA (r = –0.187, P = 0.066).
4. Discussion
Although the pathogenesis of RHD has not yet been
fully clarified, streptococcal virulence factors, individual
susceptibility, exaggerated immune response, and tissue
damage are thought to play a role in the pathogenesis (9).
There are several studies that indicate the existence
of a genetic predisposition in the development of ARF
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Table 1. Baseline characteristics and laboratory parameters of the study groups.
Patient group
(n = 50)

Control group
(n =50)

P-value

37.8 ± 7.7

35.3 ± 6.3

0.079

Mitral valve area, cm

2.3 ± 0.8

-

-

Male, n (%)

21 (42)

29 (58)

0.423

Maximum gradient of mitral valve, mmHg

10.8 ± 4.6

-

-

Mean gradient of mitral valve, mmHg

4.6 ± 2.3

-

-

Hemoglobin, g/dL

12.9 ± 1.2

13.1 ± 1.1

0.331

Creatinine, mg/dL

0.6 ± 0.1

0.7 ± 0.1

0.230

White blood cells, 103/mm3

7.3 ± 1.6

5.8 ± 0.5

<0.001

Platelets, 10 /mm

237 ± 57

307 ± 50

<0.001

TNF-α, pg/mL*

3.12 (0–58.55)

1.18 (0–11.13)

0.469

hs-CRP, mg/L*

1.58 (0.01–9.88)

0.13 (0–2.05)

<0.001

Variables
Age, years
2

3

3

Data are given as mean ± SD or n (%).TNF-α, Tumor necrosis factor alpha; hs-CRP, high sensitivity C-reactive
protein. * Mean (min–max).

Table 2. Valvular involvement in study patients.
Valvular involvement, n

n

Mitral valve

50

Mitral + aortic valve

44

Mitral + aortic + tricuspid valve

3

and RHD. Host genetic factors have been related to
susceptibility to ARF and subsequent progression to RHD
as earlier studies have shown a low attack rate (up to 3%)
of ARF after untreated streptococcal pharyngitis (10), a
relatively high concordance rate for rheumatic fever in
monozygotic twins (19%) in comparison to dizygotic twins
(2.5%) (11), and high familial incidence of ARF (12,13).
There are several studies that investigated the
relationship between ARF and HLA antigens. Ayoub et
al. reported a statistically significant increase of HLADR4 level in Caucasians and of HLA-DR2 level in African
Americans in patients with RHD (14). Anastasiou-Nana
et al. showed similar results for the relationship between
HLA-DR4 and RHD (15). Ahmed et al. observed that the
HLA-DRB1*16 allele was statistically increased in patients
with ARF (16). Conversely, Maharaj et al. reported no
differences in HLA-A, HLA-B, and HLA-DQ frequencies
between patients with severe chronic RHD and controls
(17,18).
HLA-B27 has been strongly associated with various
autoimmune diseases. Toor et al. showed that HLA-B27
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was positive in nearly 43% of ARF patients (13). Although
patients with the HLA-B27 allele were twofold higher than
among control subjects, this was not statistically significant
in our study.
There are also conflicting results in Turkey, similar
to other worldwide data. Ozkan et al. reported a positive
correlation between the expression of HLA-DR3, -DR7,
and -DRB16 and RHD development and a negative
correlation between the expression of HLA-DR5 and RHD
development in adults with chronic RHD (19). Conversely,
Karakurt et al. showed that DRB5 and DRB1*15 acted as
susceptibility factors for RHD, while DRB4 was a protective
factor against RHD (20). Olmez et al. reported that there
was a significant correlation between rheumatic fever
and HLA-A10 and HLA-B35 and a significant increase
in HLA-A10 and HLA-drw11 in patients with cardiac
involvement when compared to patients without cardiac
involvement (21). Hallioglu et al. reported that the HLA
DQA1*03 allele is a protective factor against rheumatic
fever in Turkish children (22).
There were no consistent results in the studies that
investigated the association between HLA and RHD. This
can be attributed to the earlier studies using the serological
typing method, which is unable to distinguish allelic
subgroups and can produce misleading results, rather than
molecular typing methods. These conflicting results can be
explained by the ethnic variability of HLA alleles in different
populations and the contribution of genes, showing a
different linkage disequilibrium pattern with their HLADR and HLA-DQ alleles in different populations. The
results of the studies investigating genetic susceptibility
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Table 3. HLA-B allele distributions of the patient group and the controls.
Patient group
(n = 50)

Control group
(n = 50)

P-value

HLA-B13, n (%)

4 (8)

2 (4)

0.400

HLA-B27, n (%)

4 (8)

2 (4)

0.400

HLA-B35, n (%)

18 (36)

9 (18)

0.043

HLA-B38, n (%)

4 (8)

9 (18)

0.137

HLA-B44, n (%)

2 (4)

10 (20)

0.014

HLA-B49, n (%)

7 (14)

3 (6)

0.182

HLA-B51, n (%)

15 (30)

13 (26)

0.656

HLA-B52, n (%)

2 (4)

3 (6)

0.646

against rheumatic fever and rheumatic carditis were
also adversely affected by the nonheterogeneity of the
clinical modeling of cases of ARF and RHD (6). Regional
variations of specific strains of streptococci playing a role
in the development of ARF can be considered one of the
factors that may affect the results (23).
In the present study, there was not statistically
significant difference in the presence of the HLA-B27 allele
in patients with RHD when compared to the controls. The
HLA-B35 allele was significantly more common in patients
with RHD compared with the control group. HLA-B35 is
responsible for cytotoxic T-lymphocyte-mediated immune
reactions by mobilizing the autoimmune mechanisms
(24). Therefore, we believe that there may be a relationship
between the HLA-B35 allele and rheumatic mitral valves
and the above-mentioned immune mechanism may be
responsible for this association. Investigators reported that
the incidence of ARF was significantly higher in patients
with HLA-B35 (21). This suggests that individuals with the
HLA-B35 allele may be more susceptible to development of
ARF, and therefore there may be a significantly higher risk
of RHD. The level of HLA-B44 allele was observed to be
significantly higher in the control group when compared
to the group of patients with RHD, which suggests a
possible protective role for RHD.
CRP is one of the well-known inflammatory markers.
Eastham et al. found that CRP was always present in active
RHD and proved to be a useful guide in the management
of disease (25). Chiu-Braga et al. also reported high levels
of hs-CRP in chronic rheumatic valve disease (26). Karpuz
et al. observed that the CRP level was higher in patients
with chronic RHD compared with the control group,
and they suggested that this increase was an indicator of
continuing inflammation (27). We also found that hs-CRP
levels were significantly higher in patients with RHD than
the control group. The MVA was narrower in patients with
higher hs-CRP levels.

TNF-α is a potent immunomodulator and
proinflammatory cytokine that mediates various
pathological processes (28). Yegin et al. showed an
increment in TNF-α levels in ARF patients (29). TNF-α
levels were higher in RHD patients with cardiac failure
(30). Berdeli et al. investigated the relationship between
single nucleotide polymorphisms in the promoter region
of TNF-α and ARF in hospitalized patients. No significant
difference was found in the frequencies of the TNF-α -308
G and A alleles between the patients and controls (30).
There was also no difference in TNF-α levels between the
two groups in our study. This result might be attributed to
the low number of patients.
Our study has some limitations. First, our study has
a small sample size. Second, the study is a single-center
study. Further studies including a greater number of
patients and control group members should be performed
for the confirmation of the sensitivity of HLA-B alleles and
TNF-α in patients with RHD.
This study demonstrated that patients with RHD
have a higher frequency of the HLA-B35 allele and a
lower frequency of the HLA-B44 allele. This suggests
that individuals with the HLA-B35 allele may be more
susceptible to the development of ARF, and therefore there
may be a significantly higher risk of RHD.
There are several studies showing the relationship
between HLA-B alleles and RHD. However, there are
contradictory results. For this reason, we aimed to
investigate the same subject in order to contribute to
the literature. Unlike other studies, we researched the
relationship between serum HLA-B alleles and TNF-α in
patients with RHD at the same time. This is also the first
study to investigate the relationship between TNF and
RHD in the Turkish population for a wider population
than other studies. Yegin et al. researched the TNF-α levels
in 15 RHD patients (29). They found that TNF-α levels
were higher in RHD patients with cardiac failure. In our
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study, we researched TNF-α levels for 50 patients. Berdeli
et al. researched TNF-α levels in patients with acute
rheumatic fever but not in patients with RHD (30).
Our study provides further information on the genetic
predisposition for RHD and the protective immune
responses in RHD. Further insight into the molecular
mechanisms of the disease will be a useful tool for predicting
clinical outcomes in patients with ARF and therefore may
potentially offer new means and approaches to treatment

and prophylaxis, including a potential vaccine. Therefore,
long-term follow-up and large-scale prospective studies
are needed to investigate the relationship between RHD
and HLA-B alleles.
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